HiPAL Pro, a self-administered engaging and interactive tool, supporting clinicians in diagnosing cognitive impairments has been released in the USA

HiPAL Pro is officially listed with the US Food and Drug Administration (FDA) as a computerised cognitive assessment aid

Genting TauRx Diagnostic Centre Sdn Bhd (GTD), a Malaysian based company, and its UK subsidiary, GT Diagnostics (UK) Ltd, jointly GT Diagnostics, today announced the release of HiPAL Pro, which is now available in the USA.

HiPAL Pro is a self-administered engaging and interactive tool that runs on a tablet. It supports clinicians by providing readily interpretable scores that professionally evaluate objective and subjective memory as well as mental processing speed. Through language agnostic testing, HiPAL Pro is designed to assist in the diagnosis and monitoring of dementia, in particular, Alzheimer’s disease.

Director of GTD, Dato’ Sri Tan Kong Han states “GT Diagnostics was formed to enable basic research in dementia diagnosis to transition into clinical development. With the release of our first clinical expert tool, HiPAL Pro, we see the first tangible fruit of this vision. Our dedicated team is working tenaciously towards release of more products that will transform the patient pathway in dementia in the near future.”

This is a huge milestone for GT Diagnostics. It is impressive to see what the team has achieved over the past years.

Prof Bjoern Schelter

CEO, GT Diagnostics (UK) Ltd

Prof Bjoern Schelter, CEO of GT Diagnostics (UK) Ltd confirms “This is a huge milestone for GT Diagnostics. It is impressive to see what the team has achieved over the past years.”

Dr Linda Sommerlade, Head of Operations of GT Diagnostics (UK) Ltd adds “HiPAL Pro is a tool that can be used in waiting rooms of primary care facilities or expert centres. This presents a first step in revolutionising the diagnosis of dementia. With novel treatments becoming available, the development of cutting-edge diagnostic solutions is key to make these treatments available to the right people early in the disease.”

For additional information, please visit: https://gtd2024.web-balance.co.uk/products/hipal-pro or https://hipalpro-app.com or contact Linda Sommerlade, Head of Operations at contact@gtdiag.com